Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen
Brief Summary: This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.


Options:
A: Arm Label: Abiraterone acetate plus prednisone/prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Abiraterone acetate, Drug: Prednisone/prednisolone | Arm Label: Placebo plus prednisone/prednisolone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone/prednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus prednisone/prednisolone | Intervention Type: DRUG; Name: Abiraterone acetate; Assigned to Arm(s): Abiraterone acetate plus prednisone/prednisolone | Intervention Type: DRUG; Name: Prednisone/prednisolone; Assigned to Arm(s): Abiraterone acetate plus prednisone/prednisolone, Placebo plus prednisone/prednisolone
B: Arm Label: Mitoxantrone + Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: mitoxantrone, Drug: prednisone | Arm Label: Cabazitaxel + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: cabazitaxel (XRP6258) (RPR116258), Drug: prednisone | Intervention Type: DRUG; Name: cabazitaxel (XRP6258) (RPR116258); Assigned to Arm(s): Cabazitaxel + Prednisone | Intervention Type: DRUG; Name: mitoxantrone; Assigned to Arm(s): Mitoxantrone + Prednisone | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Cabazitaxel + Prednisone, Mitoxantrone + Prednisone
C: Arm Label: Enzalutamide; Type: EXPERIMENTAL; Interventions: Drug: Enzalutamide, Drug: LHRHA or Surgical Castration | Arm Label: Conventional NSAA; Type: ACTIVE_COMPARATOR; Interventions: Drug: NSAA, Drug: LHRHA or Surgical Castration | Intervention Type: DRUG; Name: Enzalutamide; Assigned to Arm(s): Enzalutamide | Intervention Type: DRUG; Name: NSAA; Assigned to Arm(s): Conventional NSAA | Intervention Type: DRUG; Name: LHRHA or Surgical Castration; Assigned to Arm(s): Conventional NSAA, Enzalutamide
D: Arm Label: Placebo + prednisone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone | Arm Label: Abiraterone + prednisone; Type: EXPERIMENTAL; Interventions: Drug: Abiraterone acetate, Drug: Prednisone | Intervention Type: DRUG; Name: Abiraterone acetate; Assigned to Arm(s): Abiraterone + prednisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Abiraterone + prednisone, Placebo + prednisone

Answer: B